GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GNI Group Ltd (TSE:2160) » Definitions » COGS-to-Revenue

GNI Group (TSE:2160) COGS-to-Revenue : 0.20 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is GNI Group COGS-to-Revenue?

GNI Group's Cost of Goods Sold for the three months ended in Mar. 2024 was 円1,217 Mil. Its Revenue for the three months ended in Mar. 2024 was 円5,949 Mil.

GNI Group's COGS to Revenue for the three months ended in Mar. 2024 was 0.20.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. GNI Group's Gross Margin % for the three months ended in Mar. 2024 was 79.54%.


GNI Group COGS-to-Revenue Historical Data

The historical data trend for GNI Group's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GNI Group COGS-to-Revenue Chart

GNI Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.16 0.13 0.15 0.14

GNI Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.08 0.16 0.22 0.20

GNI Group COGS-to-Revenue Calculation

GNI Group's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3579.396 / 26010.571
=0.14

GNI Group's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1217.078 / 5948.569
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GNI Group  (TSE:2160) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

GNI Group's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1217.078 / 5948.569
=79.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


GNI Group COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of GNI Group's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


GNI Group (TSE:2160) Business Description

Traded in Other Exchanges
Address
Shinjuku Park Tower, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-1030
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.

GNI Group (TSE:2160) Headlines

No Headlines